TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome

Harnessing the innate power of T cells for therapeutic benefit has seen many shortcomings due to cytotoxicity in the past, but still remains a very attractive mechanism of action for immune-modulating biotherapeutics. With the intent of expanding the therapeutic window for T-cell targeting biotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrara, Stefania C., Harwardt, Julia, Grzeschik, Julius, Hock, Björn, Kolmar, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687101/
https://www.ncbi.nlm.nih.gov/pubmed/36439165
http://dx.doi.org/10.3389/fimmu.2022.1051875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687101/
https://www.ncbi.nlm.nih.gov/pubmed/36439165
http://dx.doi.org/10.3389/fimmu.2022.1051875

Ejemplares similares